Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group
Por:
Arevalo J.F., Lasave A.F., Wu L., Acon D., Farah M.E., Gallego-Pinazo R., Alezzandrini A.A., Fortuna V., Quiroz-Mercado H., Salcedo-Villanueva G., Maia M., Serrano M., Rojas S.
Publicada:
1 ene 2016
Resumen:
Background/aims To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB). Methods Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25mg IVB and had a minimum follow-up of 60months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05. Results Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1-47 injections). At 5years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved =2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost =2 lines of BCVA at 60months. Mean CMT decreased from 403.5±142.2µm at baseline to 313.7±117.7µm over 5years follow-up (p=0.0001). Conclusions The early visual gains due to IVB were not maintained 5years after treatment. © Published by the BMJ Publishing Group Limited.
Filiaciones:
Arevalo J.F.:
Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287, United States
Lasave A.F.:
Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina
Wu L.:
Retina Service, Instituto de Cirugia Ocular, San Jose, Costa Rica, Costa Rica
Acon D.:
Retina Service, Instituto de Cirugia Ocular, San Jose, Costa Rica, Costa Rica
Farah M.E.:
Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil
Gallego-Pinazo R.:
Department of Ophthalmology, Consorcio Hospital, General Universitario de Valencia, Valencia, Spain
Alezzandrini A.A.:
Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina
Fortuna V.:
Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina
Quiroz-Mercado H.:
Department of Ophthalmology, University of Colorado School of Medicine, Denver, CO, United States
Salcedo-Villanueva G.:
Department of Ophthalmology, University of Colorado School of Medicine, Denver, CO, United States
Maia M.:
Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil
Serrano M.:
Retina Service, Clin. Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela, Venezuela
Rojas S.:
Retina Service, Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico
|